TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank50
5Y CAGR-58.2%
Year-over-Year Change
Year-over-year revenue growth rate
5Y CAGR
-58.2%/yr
Long-term compound
Percentile
P50
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 2.23% |
| Q3 2025 | -18.37% |
| Q2 2025 | 41.69% |
| Q1 2025 | 226.47% |
| Q4 2024 | -36.61% |
| Q3 2024 | 95.71% |
| Q2 2024 | -5.30% |
| Q1 2024 | -92.15% |
| Q4 2023 | 85.52% |
| Q3 2023 | 23.48% |
| Q2 2023 | -53.73% |
| Q1 2023 | 119.81% |
| Q4 2022 | -7.97% |
| Q3 2022 | -17.09% |
| Q2 2022 | 34.26% |
| Q1 2022 | 5.85% |
| Q4 2021 | 18.33% |
| Q3 2021 | -15.31% |
| Q2 2021 | 40.50% |
| Q1 2021 | 154.97% |
| Q4 2020 | 174.14% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |